Neurocrine Biosciences Reports New INGREZZA Data in Tardive Dyskinesia
SAN DIEGO, June 8, 2026 Neurocrine Biosciences announced new clinical findings demonstrating the long-term effectiveness of INGREZZA® (valbenazine) capsules...
INGREZZA
Advertisement
Galmed to Acquire Colospan in Major GI MedTech Expansion
RAMAT GAN, Israel – June 8, 2026 Galmed Pharmaceuticals has entered into a definitive agreement to acquire Colospan Ltd.,...
Neurocrine Presents New INGREZZA Data Showing Rapid Improvements in Tardive Dyskinesia
SAN DIEGO, California, USA – June 8, 2026 Neurocrine Biosciences has presented new clinician-reported data demonstrating meaningful functional, physical,...
Neurocrine Defines TDIS Threshold for TD Treatment Impact
SAN DIEGO, California, April 29, 2026 Neurocrine Biosciences announced the publication of new peer-reviewed research in The Journal of...
GlycoNex Secures PMDA Nod for GNX1021 Phase 1 Trial
NEW TAIPEI CITY, TAIWAN, April 14, 2026 GlycoNex, Inc. has received approval from Japan’s Pharmaceuticals and Medical Devices Agency...
Advertisements
Revolution Medicines Reports Phase 3 Survival Gain PDAC
REDWOOD CITY, CALIFORNIA, USA, April 13, 2026 Revolution Medicines has announced positive topline results from its pivotal Phase 3...
Neurocrine Shows INGREZZA Persistence Edge in TD Study
SAN DIEGO, USA, April 14, 2026 Neurocrine Biosciences has presented new real-world evidence (RWE) demonstrating that patients treated with...
Advertisement
